Form 4: Terns Pharmaceuticals CEO Amy Burroughs Awarded Stock Options and Restricted Stock Units

Terns Pharmaceuticals CEO Amy Burroughs received stock options for 1,250,000 shares and 150,000 restricted stock units on March 1, 2024, as disclosed in a Form 4 filing.

Summary

• Amy L. Burroughs, CEO of Terns Pharmaceuticals, was granted stock options and restricted stock units (RSUs) on March 1, 2024.
• The stock options are for 1,250,000 shares with an exercise price of $7.31, expiring on February 28, 2034.
• 25% of the stock options vest on the first anniversary of March 1, 2024, and the remainder vests monthly over the following three years.
• The RSU award is for 150,000 shares of common stock.
• The RSUs vest in two tranches: 50% if the average closing price of Terns' common stock equals or exceeds $15.00 for 30 consecutive trading days, and the remaining 50% if the average closing price equals or exceeds $20.00 for 30 consecutive trading days.
• Vesting of the RSUs cannot occur before the first anniversary of Burroughs' employment and must be achieved by the fourth anniversary.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting stability and alignment of interests. The performance-based vesting of RSUs indicates confidence in the company's future prospects.

Positives

• The equity awards align the CEO's interests with those of shareholders by incentivizing stock price appreciation.
• The vesting schedules for both the stock options and RSUs encourage long-term commitment from the CEO.

Risks

• The vesting of the RSUs is contingent on achieving specific stock price targets, which may not be met.
• The value of the stock options is dependent on the company's stock price exceeding the exercise price of $7.31.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the equity awards.

Industry Context

Equity compensation is a common practice in the pharmaceutical industry to attract and retain top executive talent and align their interests with those of shareholders. The specific terms of the awards, such as vesting schedules and performance-based conditions, vary depending on the company's size, stage of development, and strategic goals.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Vesting schedules tied to stock price performance, as seen with the RSUs, are also common to incentivize executives to drive shareholder value.
• Comparable companies like Madrigal Pharmaceuticals and Viking Therapeutics also utilize stock options and RSUs in their executive compensation plans.
• The size of the grant is within the typical range for a CEO of a company of Terns' size and market capitalization.

Stakeholder Impact

• Shareholders may view the equity awards positively as they align the CEO's interests with increasing shareholder value.
• Employees may be motivated by the potential for company success and stock price appreciation.
• The awards do not directly impact customers, suppliers, or creditors.

Key Dates